If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Antineoplastic, multikinase inhibitor
ALK-positive metastatic non-small cell lung cancer†
Alectinib (selective ALK inhibitor), brigatinib, ceritinib, crizotinib
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Inhibitors of Anaplastic Lymphoma Kinase (ALK)
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals